Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18714012 | 0.92 | KEAP1 (0.48) | KEAP1NFE2L2ALDH1A1TP53TSHR | |
| SCHEMBL19947282 | 0.84 | KEAP1 (0.44) | KEAP1NFE2L2ALDH1A1TP53TSHR | |
| SCHEMBL979056 | 0.83 | KEAP1 (0.55) | KEAP1NFE2L2ALDH1A1TP53TSHR | |
| SCHEMBL32668944 | 0.83 | KEAP1 (0.55) | KEAP1NFE2L2ALDH1A1TP53TSHR | |
| SCHEMBL3870844 | 0.83 | KEAP1 (0.45) | KEAP1NFE2L2ALDH1A1TP53MAP2K1 | |
| SCHEMBL364382 | 0.81 | KEAP1 (0.48) | KEAP1NFE2L2ALDH1A1TP53TSHR | |
| SCHEMBL1045113 | 0.81 | KDM4E (0.44) | KEAP1NFE2L2ALDH1A1TP53MAP2K1 | |
| Hydrochloric Acid SCHEMBL9488278 | 0.81 | KEAP1 (0.53) | KEAP1NFE2L2ALDH1A1TP53TSHR | |
| SCHEMBL19866316 | 0.81 | TP53 (0.41) | KEAP1NFE2L2ALDH1A1TP53MAP2K1 | |
| SCHEMBL2854043 | 0.81 | CA1 (0.50) | ALDH1A1TP53TSHRCASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024192147-A2 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | ENKO CHEM, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-118488944-A | Nitrogen-containing heterocyclic compound having Nrf2 activation | 中外制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| US-6617344-B2 | Suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment, and also for the treatment of angina pectoris. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-07-24 | — | — | US | disclosed |
| CN-1373757-A | Heterocyclically substd, benzoylguanidine, method for production thereof, use thereof as medicament or means of diagnosis and medicaments contg. same | AVENTIS PHARMA GMBH (DE) | 2002-10-09 | — | — | CN | disclosed |
| EP-1226124-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS A MEDICAMENT OR MEANS OF DIAGNOSIS AND A MEDICAMENT CONTAINING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2002-07-31 | — | — | EP | disclosed |
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2002-07-25 | — | — | US | disclosed |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2001-12-06 | — | — | US | disclosed |
| WO-2001030761-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS A MEDICAMENT OR MEANS OF DIAGNOSIS AND A MEDICAMENT CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
| US-6057322-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | KEAP1 1233/4885NFE2L2 529/4885ALDH1A1 66/4885 |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | KEAP1 1/4885NFE2L2 2/4885ALDH1A1 1411/4885 |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | KEAP1 1233/4885NFE2L2 529/4885ALDH1A1 66/4885 |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | TNNI3, HBG1, TNNT2 | KEAP1 1233/4885NFE2L2 529/4885ALDH1A1 66/4885 |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | KEAP1 1/4885NFE2L2 2/4885ALDH1A1 1411/4885 |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | KEAP1 1/4885NFE2L2 2/4885ALDH1A1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.